• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Business & Finance

Can This Beaten-Down Stock Bounce Back in 2025? todayheadline

January 23, 2025
in Business & Finance
Reading Time: 3 mins read
A A
0
PFE Operating Revenue (Quarterly YoY Growth) Chart
4
SHARES
9
VIEWS
Share on FacebookShare on Twitter


In 2022, pharmaceutical giant Pfizer (PFE -2.37%) became the first healthcare company to generate $100 billion in annual sales. But since that notable achievement, its financial results have fallen off a cliff, as has its stock price. Pfizer has made progress, especially on the clinical and regulatory fronts, through acquisitions and internally developed programs. But nothing has stopped the bleeding — yet.

Could 2025 be different? Let’s see whether the drugmaker can finally turn things around this year.

Will financial results be a catalyst?

Pfizer’s woes started because it couldn’t keep delivering the kinds of financial results it did during the earlier pandemic years, or even anything close to that. If the drugmaker can at least consistently grow its revenue and earnings at a good clip, that might lead more investors to buy the stock at current levels.

It’s made some improvements along those lines this year. In the second and third quarters, after not doing so for several periods in a row, the company’s top line moved in the right direction:

PFE Operating Revenue (Quarterly YoY Growth) data by YCharts.

However, Pfizer’s revenue guidance for 2025 doesn’t look particularly exciting. The company expects its top line to come in between $61 billion and $64 billion — the same projection it made for the full fiscal year 2024. In other words, 2025 revenue will stay more or less flat compared to 2024, based on the company’s own guidance.

The good news is that Pfizer is projecting its adjusted earnings per share for 2025 to be in the range of $2.80 to $3, growing between 10% and 18% compared to 2024. Still, based on its guidance, those financial results won’t help the stock rise significantly this year unless Pfizer meaningfully beats its projections. And if it fails to live up to them, the share price will drop even more.

Looking at potential pipeline progress

Clinical and regulatory progress can jolt a drugmaker’s stock price. That hasn’t exactly happened for Pfizer in the past couple of years, despite the many approvals it won, because none of its new products will generate life-changing sales. Could that change in 2025?

If it does, it might be because of Pfizer’s work in the weight loss market. The drugmaker is developing danuglipron, a potential once-daily oral weight management medicine. Danuglipron is currently in phase 1 studies (previous versions of the drug went as far as phase 2 trials), and Pfizer could report data this year.

If the investigational therapy does well — even in just a phase 1 study — it could positively affect Pfizer’s stock performance, since the anti-obesity market is currently the hottest in the pharmaceutical industry. The current leading treatments in the weight management market are administered via weekly injections. There is a demand for oral options, something many drugmakers are working on.

Could Pfizer make enough headway along those lines in 2025 to jolt its share price? It’s hard to predict these things, but it’s worth noting that many other drugmakers are also working on potential oral drugs for weight management. Pfizer has a variety of other pipeline candidates, especially in oncology, but investors might not react as positively to progress on these other fronts, since the anti-obesity market looks especially attractive and is growing incredibly fast right now.

The more important question

Pfizer might not perform particularly well this year. Its financial results likely won’t be outstanding, and there’s no guarantee that its more promising pipeline candidates will deliver the kinds of results investors want to see.

That said, the company has been hard at work, slowly but surely setting up a foundation for the future. Eventually, its pipeline progress will likely pan out, especially in oncology. It will be able to replace older products whose sales aren’t growing as fast as they once were. It should also decrease its exposure to the coronavirus market, which, though still contributing meaningfully to its top line, can be somewhat inconsistent.

Lastly, Pfizer is a strong dividend stock. It offers a forward yield of around 6.5% — compared to the S&P 500‘s average of 1.3% — and has grown its payouts by 53.6% in the past decade.

Pfizer hasn’t been attractive to growth-oriented investors, or to those with a short investing time horizon. But those looking for blue-chip dividend payers to buy and hold for five years or more should seriously consider investing in the stock.

Tags: BeatenDownbounceStocktodayheadline
Previous Post

Rheinmetall target raised at UBS as Trump continues to push for higher defense spe By Investing.com todayheadline

Next Post

Auburn now unanimous No. 1; Duke moves to No. 2 todayheadline

Related Posts

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud todayheadline

June 7, 2025
4
A rocket with a glass piggy bank on top with coins inside of it.

Clamoring to Invest in SpaceX but Can’t? Consider Buying Stock in This Competitor That Just Upped Its National Defense Game. todayheadline

June 7, 2025
6
Next Post
Auburn No. 1 in AP men's poll; Georgia in, 1st time since 2011

Auburn now unanimous No. 1; Duke moves to No. 2 todayheadline

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024

Police ID man who died after Corso Italia fight

December 23, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud todayheadline

June 7, 2025
Abyssinian kitten closing its eyes in contentment as its petted by its owner.

The Genetic Mystery of Why Cats Purr May Finally Be Solved : ScienceAlert todayheadline

June 7, 2025
A white sphere sits on a black legged stand on top of a white surface with black buttons on one side of the sphere.

Sega Toys Homestar Classic star projector review

June 7, 2025
old hands

Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

June 7, 2025

Recent News

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud todayheadline

June 7, 2025
4
Abyssinian kitten closing its eyes in contentment as its petted by its owner.

The Genetic Mystery of Why Cats Purr May Finally Be Solved : ScienceAlert todayheadline

June 7, 2025
5
A white sphere sits on a black legged stand on top of a white surface with black buttons on one side of the sphere.

Sega Toys Homestar Classic star projector review

June 7, 2025
4
old hands

Resident-to-resident aggression is common in nursing homes. Here’s how we can improve residents’ safety

June 7, 2025
5

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud

Trump says his relationship with Musk is over, slamming the door on the once-staunch ally who tried to de-escalate their feud todayheadline

June 7, 2025
Abyssinian kitten closing its eyes in contentment as its petted by its owner.

The Genetic Mystery of Why Cats Purr May Finally Be Solved : ScienceAlert todayheadline

June 7, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co